{"id":"NCT01000662","sponsor":"NYU Langone Health","briefTitle":"Study Comparing Whole Breast Radiotherapy With a Daily Versus a Weekly Tumor","officialTitle":"Phase III Study Comparing Whole Breast Radiotherapy With a Daily Tumor Red Boost","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-03","primaryCompletion":"2012-07","completion":"2017-06-14","firstPosted":"2009-10-23","resultsPosted":"2015-05-29","lastUpdate":"2020-08-06"},"enrollment":412,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Breast Cancer"],"interventions":[{"type":"RADIATION","name":"Daily Radiation Therapy","otherNames":[]},{"type":"RADIATION","name":"Weekly Radiation Therapy","otherNames":[]}],"arms":[{"label":"ARM 1 daily boost","type":"ACTIVE_COMPARATOR"},{"label":"ARM 2 weekly boost","type":"ACTIVE_COMPARATOR"}],"summary":"All patients (with Stages 0-II breast cancer) will receive an accelerated three week regimen of prone whole breast radiotherapy. The study intends to test the hypothesis that a weekly boost to the tumor bed, delivered on Friday, before the weekend break, is as well tolerated as the daily boost during accelerated prone radiotherapy.","primaryOutcome":{"measure":"Number of Participants With Acute Radiation Toxicities Recorded According to Radiation Therapy Oncology Group (RTOG)","timeFrame":"Day 60","effectByArm":[{"arm":"ARM 1 Daily Boost","deltaMin":22,"sd":null},{"arm":"ARM 2 Weekly Boost","deltaMin":16,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":3,"countries":["United States"]},"refs":{"pmids":["27131077","24161428","27045811"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":202},"commonTop":["Retraction/Atrophy (Grade 1)","Fibrosis (Grade 1)","Pigmentation Change (Grade 1)","Pain (Grade 1)","Telangiectasia (Grade 1)"]}}